Program
infigratinib
Also written as “Infigratinib”, “BGJ398” and “infigratinib 0.128 mg/kg/day”.
Its studies are mostly in Achondroplasia · Mucopolysaccharidosis IV · Stomach Neoplasms · Cholangiocarcinoma · Urinary Bladder Neoplasms, led by 5 companies.
Drug pageInfigratinib: every studyMany companies study it; this page follows only the 17 they lead. All 30 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBioits history only | 83 open or running | phase 3since Dec 10, 2018 | May 12, 2014 | Jan 2027phase 3 · NCT06873035 |
| Novartisits history only | 50 open or running | phase 2since Oct 28, 2013 | Oct 27, 2009 | none ahead |
| LianBioits history only | 20 open or running | phase 2since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Helsinn Healthcareits history only | 10 open or running | phase 2since Jan 12, 2022 | Jan 12, 2022 | none ahead |
| Pfizerits history only | 10 open or running | phase 2since Apr 28, 2014 | Apr 28, 2014 | none ahead |
Also a collaborator on its studies: Labcorp Corporation of America.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Oct 27, 2009.
- Oct 28, 2013Phase 2 study in GlioblastomaNovartis · NCT01975701 · 26 enrolled · United States, Australia, Belgium and more
- Apr 28, 2014Pfizer’s first study: phase 2 study in MelanomaNew to PfizerPfizer · NCT02159066 · 158 enrolled · United States, Australia, Canada and more
- May 12, 2014BridgeBio’s first study: phase 2 study in CholangiocarcinomaNew to BridgeBioBridgeBio · NCT02150967 · 143 enrolled · United States, Belgium, Germany and more
- Jun 6, 2014Phase 2 study in Hematologic NeoplasmsNovartis · NCT02160041 · 84 enrolled · United States
- Dec 10, 2018Phase 3 study in CholangiocarcinomaBridgeBio · NCT03773302 · 48 enrolled · United States, Australia, Belgium and more
- Dec 2, 2019Phase 3 study in Upper Tract Urothelial CarcinomasBridgeBio · NCT04197986 · 39 enrolled · United States, Belgium, Bulgaria and more
- Jan 29, 2020Phase 2 study in AchondroplasiaBridgeBio · NCT04265651 · 84 enrolled · United States, Australia, Canada and more
- Jul 28, 2021LianBio’s first study: phase 2 study in Stomach NeoplasmsNew to LianBioLianBio · NCT05019794 · 80 enrolled · China
- Nov 22, 2021Phase 2 study in AchondroplasiaBridgeBio · NCT05145010 · 325 planned · United States, Argentina, Australia and more
- Jan 12, 2022Helsinn Healthcare’s first study: phase 2 study in Central Nervous System NeoplasmsNew to Helsinn HealthcareHelsinn Healthcare · NCT05222165 · United States, Canada, Germany
- Nov 29, 2023Phase 2 study in Stomach NeoplasmsLianBio · NCT06206278 · 6 enrolled · China
- Nov 29, 2023Phase 3 study in AchondroplasiaBridgeBio · NCT06164951 · 114 enrolled · United States, Argentina, Australia and more
- Feb 18, 2025Phase 3 study in HypochondroplasiaBridgeBio · NCT06873035 · 24 planned · United States, Australia, Canada and more
- Jan 19, 2026Phase 2 study in HypochondroplasiaBridgeBio · NCT07393373 · 135 planned · United States, Australia, Canada and more
Ahead
- Jan 2027Primary completion: phase 3 study in HypochondroplasiaBridgeBio · NCT06873035
- Dec 1, 2031Primary completion: phase 2 study in AchondroplasiaBridgeBio · NCT05145010
- May 31, 2036Primary completion: phase 2 study in HypochondroplasiaBridgeBio · NCT07393373
TargetBeta
“Fibroblast growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07393373Hypochondroplasia · United States, Australia, Canada and more | 2 | By invitation | BridgeBio | May 31, 2036 | 135 |
| NCT06873035Hypochondroplasia · United States, Australia, Canada and more | 3 | By invitation | BridgeBio | Jan 2027 | 24 |
| NCT06206278Stomach Neoplasms · China | 2 | Terminated | LianBio | May 31, 2024 | 6 |
| NCT06164951Achondroplasia · United States, Argentina, Australia and more | 3 | Completed | BridgeBio | Dec 18, 2025 | 114 |
| NCT05222165Central Nervous System Neoplasms · United States, Canada, Germany | 2 | Withdrawn | Helsinn Healthcare | Dec 16, 2022 | 0 |
| NCT05145010Achondroplasia · United States, Argentina, Australia and more | 2 | By invitation | BridgeBio | Dec 1, 2031 | 325 |
| NCT05019794Stomach Neoplasms · China | 2 | UNKNOWN | LianBio | Dec 30, 2022 | 80 |
| NCT04265651Achondroplasia · United States, Australia, Canada and more | 2 | Completed | BridgeBio | Oct 21, 2024 | 84 |
| NCT04197986Upper Tract Urothelial Carcinomas · United States, Belgium, Bulgaria and more | 3 | Terminated | BridgeBio | Feb 28, 2023 | 39 |
| NCT03773302Cholangiocarcinoma · United States, Australia, Belgium and more | 3 | Terminated | BridgeBio | Mar 2, 2023 | 48 |
| NCT02160041Hematologic Neoplasms · United States | 2 | Terminated | Novartis | Apr 30, 2018 | 84 |
| NCT02150967Cholangiocarcinoma · United States, Belgium, Germany and more | 2 | Terminated | BridgeBio | Mar 1, 2021 | 143 |
| NCT02159066Melanoma · United States, Australia, Canada and more | 2 | Completed | Pfizer | Jan 10, 2023 | 158 |
| NCT01975701Glioblastoma · United States, Australia, Belgium and more | 2 | Completed | Novartis | Oct 3, 2018 | 26 |
| NCT01928459Breast Neoplasms · United States, Australia, Belgium and more | 1 | Completed | Novartis | Aug 2016 | 62 |
| NCT01697605Tumor With Alterations of the FGF-R · China, Japan | 1 | Completed | Novartis | Feb 7, 2019 | 9 |
| NCT01004224Lung Neoplasms · United States, Australia, Austria and more | 1 | Completed | Novartis | Oct 8, 2018 | 208 |
How it is read
Names in the registry
- “Infigratinib”, 7 entries
- “BGJ398”, 7 entries
- “infigratinib 0.128 mg/kg/day”, 1 entry
- “infigratinib 0.25 mg/kg/day”, 1 entry
- “Infigratinib 0.25 mg/kg/day”, 1 entry
Conditions, from the studies’ own filings
- Achondroplasia, 3 studies
- Mucopolysaccharidosis IV, 2 studies
- Stomach Neoplasms, 2 studies
- Cholangiocarcinoma, 2 studies
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.